References
- Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61:1447–1453.
- Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of familial mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9:553–555.
- Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9:473–483.
- Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011;70:495–499.
- K Iy M, Jiuchi Y, Iwanaga N, et al. Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Res Ther. 2016;30:175.
- Papadopoulos VP, Giaglis S, Mitroulis I, et al. The population genetics of familial mediterranean fever: a meta-analysis study. Ann Hum Genet. 2008;72:752–761.
- Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227–253.
- French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31.
- The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797–807.
- Infevers. Available from: http://fmf.igh.cnrs.fr/ISSAID/infevers/
- Yang J, Xu H, Shao F. Immunological function of familial Mediterranean fever disease protein Pyrin. Sci China Life Sci. 2014;57:1156–1161.
- Grandemange S, Aksentijevich I, Jeru I, et al. The regulation of MEFV expression and its role in health and familial Mediterranean fever. Genes Immun. 2011;12:497–503.
- Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103:9982–9987.
- Booth DR, Gillmore JD, Lachmann HJ, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM. 2000;93:217–221.
- Chae JJ, Cho YH, Lee GS, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity. 2011;34:755–768.
- Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17:914–921.
- Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014;513:237–241.
- Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.
- Ozkan E, Okur O, Ekmekci A, et al. A new approach to the treatment of periodic fever. Med Bull Istanbul. 1972;5:44–49.
- Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934–937.
- Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291:932–934.
- Zemer D, Livneh A, Danon YL, et al. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34:973–977.
- Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48–59.
- Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr. 2012;161:1142–1146.
- Slobodnick A, Shah B, Pillinger MH, et al. Colchicine: old and new. Am J Med. 2015;128:461–470.
- Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659–664.
- Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119:e474–83.
- Korkmaz C, Ozdogan H, Kasapcopur O, et al. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002;61:79–81.
- Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746–750.
- Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF–definition, causes and suggested solutions. Clin Exp Rheumatol. 2008;26:S49–51.
- Ozen S, Demirkaya E, Duzova A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73:897–901.
- Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43:387–391.
- Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644–651.
- Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004;22:S37–40.
- Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int. 2006;27:197–199.
- Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24:S99–103.
- Fujikawa K, Migita K, Tsukada T, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl 77):150–151.
- Umeda M, Aramaki T, Fujikawa K, et al. Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis. Int J Rheum Dis. 2015 Oct 20. DOI:10.1111/1756-185X.12776.
- Van Der Hilst J, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75–80.
- Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157:533–541.
- De Benedetti F, Anton J, Ben-Chetrit E, et al. Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): results from a Phase 3, Pivotal, Umbrella Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-with-periodic-fever-syndromes-colchicine-resistant-fmf-hidsmkd-and-traps-results-from-a-phase-3-pivotal-umbrella-trial/.
- De Benedetti F, Frenkel J, Calvo I, et al. Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-with-colchicine-resistant-familial-mediterranean-fever-hyper-immunoglobulin-d-syndromemevalonate-kinase-deficiency-and-tnf-receptor-associated-periodic/.
- Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine resistant familial Mediterranean fever - A randomized, double blind, placebo-controlled trial. Arthritis Rheumatol. 2016 cited 2016 Nov 22. DOI:10.1002/art.39995.
- Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
- Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–567.
- Drug information. Available from: https://www.uptodate.com/contents/anakinra-drug- information?source=search_result&search=anakinra&selectedTitle=1~92
- Drug information. Available from: https://www.uptodate.com/contents/rilonacept-drug-information?source=search_result&search=rilonacept&selectedTitle=1~20
- Drug information. Available from: https://www.uptodate.com/contents/canakinumab-drug-information?source=search_result&search=canakinumab&selectedTitle=1~21
- Kone-Paut I, Galeotti C. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2014;10:7–18.
- Georgin-Lavialle S, Stankovic Stojanovic K, Bachmeyer C, et al. Spondyloarthritis associated with familial Mediterranean fever: successful treatment with anakinra. Rheumatology (Oxford). 2017;56(1):167–169.
- Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
- Ozdogan H, Ugurlu S. The emerging treatments in familial Mediterranean fever. In: Gattorno M, editor. Familial Mediterranean fever. Switzerland: SpringerInternational Publishing; 2015. p. 137–158.
- Espildora-Hernandez J, Abarca-Costalago M. Familial mediterranean fever treated with anakinra: A case report. Reumatol Clin. 2016 [cited 2016 Nov 20]. English, Spanish. DOI:10.1016/j.reuma.2016.06.001.
- Kucuksahin O, Yildizgoren MT, Ilgen U, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol. 2017;27(2):350–355.
- Abbara S, Georgin-Lavialle S, Stankovic Stojanovic K, et al. Association of hidradenitis suppurativa and familial Mediterranean fever: A case series of 6 patients. Joint Bone Spine. 2017;84(2):159–162.
- Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652.
- Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–2452.
- Lovell DJ, Giannini EH, Aor R, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486–2496.
- Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford). 2013;52:1285–1292.
- Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81–89.
- Gram H. Preclinical characterization and clinical development of ILARIS((R)) (canakinumab) for the treatment of autoinflammatory diseases. Curr Opin Chem Biol. 2016;32:1–9.
- Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70:2095–2102.
- Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–2406.
- Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839–1848.
- Sun H, Van LM, Floch D, et al. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. J Clin Pharmacol. 2016;56(12):1516–1527.
- Chakraborty A, Van LM, Skerjanec A, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol. 2013;53:1240–1251.
- Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet. 2012;51:e1–18.
- Alten R, Gram H, La J, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R67.
- Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009;206:1029–1036.
- Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
- Frenkel JAJ, Livneh A, Ben-Chetrit E, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: results from a Phase III Pivotal Umbrella Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/pharmacokinetic-and-pharmacodynamic-characteristics-of-canakinumab-in-patients-with-periodic-fever-syndromes-results-from-a-phase-iii-pivotal-umbrella-trial/.
- Mitroulis I, Skendros P, Oikonomou A, et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70:1347–1348.
- Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265–271.
- Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford). 2012;51:1041.
- Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015;9:1983–1987.
- Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean. Fever Inflammation. 2015;38:27–31.
- Basaran O, Uncu N, Celikel BA, et al. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015;25:621–624.
- Eroglu FK, Besbas N, Topaloglu R, et al. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015;35:1733–1737.
- Ozcakar ZB, Ozdel S, Yilmaz S, et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35:441–446.
- Sozeri B, Gulez N, Ergin M, et al. The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever. Mol Cell Pediatr. 2016;3:33.
- Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014;66:3241–3243.
- Gul A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243.
- Ugurlu S, Seyahi E, Hatemi G, et al. Canakinumab Therapy in Patients with Familial Mediterranean Fever [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/canakinumab-therapy-in-patients-with-familial-mediterranean-fever-2/.
- Laskari K, Boura P, Dalekos G, et al. The Interleukin-1 Inhibitor Canakinumab for Familial Mediterranean Fever: long-Term Beneficial Effect in a Cohort of 13 Patients [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/the-interleukin-1-inhibitor-canakinumab-for-familial-mediterranean-fever-long-term-beneficial-effect-in-a-cohort-of-13-patients/
- Gul A, Ozdogan H, Kasapcopur O, et al. Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/quality-of-life-changes-with-canakinumab-therapy-in-adults-with-colchicine-resistant-fmf/
- Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2016 [cited 22 Nov 2016]. DOI:10.1136/annrheumdis-2015-209031.
- Simon A, Shcherbina A, Anton J, et al. Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov 22]. Available from: http://acrabstracts.org/abstract/effect-of-canakinumab-treatment-on-health-related-quality-of-life-in-patients-with-periodic-fever-syndromes/
- Hashkes P, Butbul Aviel Y, Lubin S, et al. A76: long‐Term Efficacy of Canakinumab in Childhood Colchicine Resistant Familial Mediterranean Fever. Arthritis Rheumatol. 2014;66(S3):S108–S108.
- Hosono K, Okami N, Sasajima T, et al. A 3-year interim analysis of post-marketing all-patient surveillance of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome. Clin Rheumatol Relat Res. 2016;28:53–65.
- Kuemmerle-Deschner J, Hoffman H, Hawkins PN, et al. Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry. Pediatr Rheumatol. 2015;13(1):1.
- Youngstein T, Hoffmann P, Lane T, et al. International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors. Pediatr Rheumatol. 2015;13(1):1.
- Akse-Onal V, Sag E, Ozen S, et al. Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better? Eur J Pediatr. 2010;169:971–974.
- Belkhir R, Moulonguet-Doleris L, Hachulla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146:825–826.
- Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016;75:1051–1056.
- Haviv R, Hashkes PJ. Canakinumab investigated for treating familial Mediterranean fever. Expert Opin Biol Ther. 2016;16:1425–1434.
- Eurofever project. Available from: http://www.printo.it/eurofever